Considering Histologic Remission in Ulcerative Colitis as a Long-Term Target.
Christopher Pavel1,2, Mircea Mihai Diculescu1,3, Alex-Emilian Stepan4
1Department of Gastroenterology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Journal of Clinical Medicine
|January 11, 2024
Summary
Monitoring inflammatory bowel disease (IBD) activity is difficult. Histologic healing, while not a formal target, is crucial for ulcerative colitis (UC) long-term outcomes and may become the new standard.
Area of Science:
- Gastroenterology
- Pathology
Background:
- Clinical and endoscopic assessments often underestimate inflammatory bowel disease (IBD) activity.
- Endoscopic remission does not always correlate with long-term disease course, as patients may relapse despite normal mucosa.
Purpose of the Study:
- To highlight the emerging importance of histologic healing in managing ulcerative colitis (UC).
- To address the need for standardized and practical approaches to assessing histologic remission in UC.
Main Methods:
- Review of current literature and consensus guidelines (e.g., STRIDE-II).
- Analysis of the limitations of existing endoscopic and clinical markers for IBD activity.
Main Results:
- Histologic healing is increasingly recognized as a significant factor in the long-term prognosis of UC.
- Current definitions and scoring systems for histologic remission lack standardization, leading to clinical ambiguity.
Conclusions:
- Histologic healing is poised to become a formal target for UC management.
- A standardized, practical approach to histopathological assessment is urgently required for consistent clinical application and improved patient outcomes.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:21Inflammatory Bowel Disease V: Surgical Management
147
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
147
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
187
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
187